Imatinib resistance in chronic myeloid leukemia due to a rare mutation

Leuk Lymphoma. 2017 Jul;58(7):1750-1752. doi: 10.1080/10428194.2016.1256479. Epub 2016 Nov 20.

Authors

Priyavadhana Balasubramanian¹, Anita Chopra¹, Deepak Verma¹, Indresh K Singh¹, Akash Kumar², Atul Sharma², Rajive Kumar¹

Affiliations

¹ a Department of Laboratory Oncology , Dr. BRAIRCH, All India Institute of Medical Sciences , New Delhi , India.
² b Department of Medical Oncology , Dr. BRAIRCH, All India Institute of Medical Sciences , New Delhi , India.

PMID: 27868464
DOI: 10.1080/10428194.2016.1256479

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Alleles
Antineoplastic Agents / pharmacology*
Cell Line, Tumor
DNA Mutational Analysis
Drug Resistance, Neoplasm / genetics*
Fusion Proteins, bcr-abl / chemistry
Fusion Proteins, bcr-abl / genetics*
Humans
Imatinib Mesylate / pharmacology*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
Male
Mutation*
Protein Kinase Inhibitors / pharmacology*

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Imatinib Mesylate
Fusion Proteins, bcr-abl